1. Home
  2. PHAR vs ARRY Comparison

PHAR vs ARRY Comparison

Compare PHAR & ARRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$17.20

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Array Technologies Inc.

ARRY

Array Technologies Inc.

HOLD

Current Price

$8.88

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
ARRY
Founded
1988
1989
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
ARRY
Price
$17.20
$8.88
Analyst Decision
Strong Buy
Buy
Analyst Count
2
20
Target Price
$38.00
$10.38
AVG Volume (30 Days)
27.7K
5.6M
Earning Date
11-06-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$362,274,000.00
$1,333,329,000.00
Revenue This Year
$25.19
$40.97
Revenue Next Year
$4.47
$13.09
P/E Ratio
$2,989.65
N/A
Revenue Growth
26.78
35.75
52 Week Low
$7.50
$3.76
52 Week High
$18.30
$10.47

Technical Indicators

Market Signals
Indicator
PHAR
ARRY
Relative Strength Index (RSI) 51.28 48.48
Support Level $16.55 $8.94
Resistance Level $17.37 $9.92
Average True Range (ATR) 0.68 0.57
MACD -0.09 -0.08
Stochastic Oscillator 41.95 26.10

Price Performance

Historical Comparison
PHAR
ARRY

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ARRY Array Technologies Inc.

Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.

Share on Social Networks: